Decibel Signs Hilltop Leaf Deal to Bring Two Cannabis Brands to UK

Decibel Cannabis Company Inc. announced on October 8, 2026 that it has entered into a brand licensing agreement with Hilltop Leaf Ltd. to launch its flower portfolio in the United Kingdom, granting Hilltop a limited license over its General Admission and Standard Issue brands in the UK.

The two companies expect to introduce an initial portfolio of fifteen General Admission and Standard Issue product lines alongside six Hilltop Leaf branded product lines in the fourth quarter of 2026, according to the licensing announcement. The launch timing, the number of product lines and the timing of the initial shipment are stated expectations that the company identifies as forward-looking, not completed milestones.

Under the structure Decibel described, it will export finished, packaged medical products to the UK, enabled by what the company called an end-to-end EU GMP qualified supply chain. Decibel stated that both companies comply with the strict regulations required to supply medical-grade, quality-assured cannabis-based products for medicinal use, known as CBPMs, into the UK market. The company characterized the agreement as further development of its international platform and part of its commitment to building globally recognized brands and a diversified revenue stream with trusted partners.

Kris Newell, Decibel’s chief operating officer, said the partnership “brings together two teams with a shared commitment to quality and consistency.” Newell said Decibel has built General Admission into one of Canada’s most recognized cannabis brands and Standard Issue into one of the fastest-growing, while Hilltop has established itself as a trusted partner to prescribers and patients across the UK medical market. He said the companies look forward to broadening both portfolios over time as the UK market continues to develop.

Hamish Clegg, chief executive officer of Hilltop Leaf, said the companies have done business together for several years and that shared values and a mutual focus on quality assurance and planning have brought them closer. “By pairing our brands, EU GMP supply chain and established UK platform we expect to bring a quality-assured, consistent and differentiated portfolio to meet the fast-growing demands from UK patients,” Clegg said.

Hilltop Leaf’s Licence and UK Role

According to a company description provided by Hilltop for the announcement, Hilltop Leaf is a UK pharmaceutical cannabinoid company and GMP-certified importer and distributor supplying cannabis-based products for medicinal use to the UK medical market. Operating under a GMP certificate, Hilltop manages the importation and distribution of finished medical cannabis products and works with prescribers, clinics and pharmacies across the UK.

On its own website, Hilltop Leaf describes itself as a private medicinal cannabis cultivation and extraction business for CBPMs based in Scotland, and states that it holds a Manufacturers “Specials” Licence granted by the Medicines and Healthcare Products Regulatory Agency under MS number MS 54236. The company states that its plants are grown to GAcP standards with EU GMP drying and processing, and that its mission is to create a leading cannabis-based medicinal product accessible to patients in the UK and Europe at a reasonable price.

Decibel’s Footprint and International Results

Decibel is a consumer-focused cannabis company built on the General Admission, Qwest and Standard Issue brands, with a foundation in the Canadian adult-use market. It operates a processing and manufacturing facility in Calgary, Alberta, a cultivation facility in Battleford, Saskatchewan, and an EU GMP licensed cultivation and processing facility in Chatham, Ontario.

The UK agreement follows what Decibel reported as a record second quarter. In its August 20, 2026 results release, the company reported record net revenue of $35.6 million, up 19% year over year, record international sales of $10.6 million, up 72%, and record adjusted EBITDA of $7.8 million. Its listed second-quarter milestones included adding multiple SKUs of finished vapes for customers in the UK market, 16+ international customers with executed supply agreements, 50+ GACP cultivators onboarded, and 60 tons per annum of flower processing capacity at roughly 34% utilization. Decibel said its AgMedica EU GMP certified platform continued to perform well above its original underwriting case, and it raised full-year 2026 guidance to net revenue of $132 million to $137 million and adjusted EBITDA of $28 million to $32 million.

The announcement also sets out stated risks to the UK plan, including satisfaction of international regulatory requirements and applicable product testing; delays in obtaining, or failure to obtain, export permits or import licences; reliance on Hilltop as Decibel’s licensee and distributor in the UK; possible termination of the license agreement; and potential changes to UK regulation of cannabis-based products for medicinal use.